SCYNEXIS Inc

NASDAQ:SCYXUnited States

Mar 28, 2024

Show headlines and story abstract

• SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday Mar 28, 2024 by GlobeNewswire

  4:01PM ET on Thursday Mar 28, 2024 by GlobeNewswire
  Companies Mentioned: SCYX

• SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday Mar 28, 2024 by Dow Jones

  4:01PM ET on Thursday Mar 28, 2024 by Dow Jones
  Companies Mentioned: SCYX
  
  Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: SCYNEXIS's expectation that it will have a cash runway of more than two years; delivery of clinical study reports to GSK in the first half of 2024, anticipated initiation of Phase I clinical studies of SCY-247 in the second half of 2024; and the resumption of the MARIO study. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 31, 2023, and form 10-Q for the quarter ending September 30(th) , 2023, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
  

• Press Release: SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday Mar 28, 2024 by Dow Jones

  4:01PM ET on Thursday Mar 28, 2024 by Dow Jones
  Companies Mentioned: SCYX
  
  Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: SCYNEXIS's expectation that it will have a cash runway of more than two years; delivery of clinical study reports to GSK in the first half of 2024, anticipated initiation of Phase I clinical studies of SCY-247 in the second half of 2024; and the resumption of the MARIO study. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 31, 2023, and form 10-Q for the quarter ending September 30(th) , 2023, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.